Cargando…
Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model
CD44, a transmembrane receptor reported to be involved in various cellular functions, is overexpressed in several cancer types and supposed to be involved in the initiation, progression and prognosis of these cancers. Since the sequence of events following the blockage of the CD44-HA interaction has...
Autores principales: | Maisel, Daniela, Birzele, Fabian, Voss, Edgar, Nopora, Adam, Bader, Sabine, Friess, Thomas, Goller, Bernhard, Laifenfeld, Daphna, Weigand, Stefan, Runza, Valeria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963023/ https://www.ncbi.nlm.nih.gov/pubmed/27463372 http://dx.doi.org/10.1371/journal.pone.0159716 |
Ejemplares similares
-
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016) -
Biobanking in Israel 2016–17; expressed perceptions versus real life enrollment
por: Koren, Gideon, et al.
Publicado: (2017) -
CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model
por: Mayr, Lisa, et al.
Publicado: (2017) -
Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
por: Herting, Frank, et al.
Publicado: (2014) -
Alternative splicing and protein structure evolution
por: Birzele, Fabian, et al.
Publicado: (2008)